Maureen G. Conlan

Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial

François‐Clément Bidard, Virginia Kaklamani, Patrick Neven et al. · Journal of Clinical Oncology · 2022 · 695 citations · Full text

Medicine, Oncology, Pharmacology +15

Associations of Factor VIII and von Willebrand Factor with Age, Race, Sex, and Risk Factors for Atherosclerosis

Maureen G. Conlan, Aaron R. Folsom, Andrea Finch et al. · Thrombosis and Haemostasis · 1993 · 439 citations

Public Health, Community Health, Clinical Epidemiology +12

Population correlates of plasma fibrinogen and factor VII, putative cardiovascular risk factors

A. R. Folsom, Kesheng Wu, C DAVIS et al. · Atherosclerosis · 1991 · 326 citations

Medicine, Cardiology, Hematology +12

Bone marrow involvement by non-Hodgkin's lymphoma: the clinical significance of morphologic discordance between the lymph node and bone marrow. Nebraska Lymphoma Study Group.

Maureen G. Conlan, M. Bast, Jamés O. Armitage et al. · Journal of Clinical Oncology · 1990 · 186 citations

Medicine, Hematology, Pathology +16

Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial

Edward L. Snyder, Jeffrey McCullough, Sherrill J. Slichter et al. · Transfusion · 2005 · 122 citations

Medicine, Hematology, Oncology +17